Trials / Completed
CompletedNCT01180530
Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes
A Multicentre, Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction of Insulin Therapy in Children and Adolescents With Diabetes Mellitus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 358 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical complaints related to adverse reactions). Study duration: 12-18 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | NovoPen Echo® | Prescribed insulin treatment delivered by NovoPen Echo® |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-08-12
- Last updated
- 2017-02-08
Locations
5 sites across 4 countries: Canada, Finland, Israel, Sweden
Source: ClinicalTrials.gov record NCT01180530. Inclusion in this directory is not an endorsement.